PROJECT TITLE :

Preparation and in vitro investigation of antigastric cancer activities of carvacrol-loaded human serum albumin nanoparticles

ABSTRACT:

In this study, carvacrol-loaded human serum albumin (HSA) nanoparticles were developed and characterised. Nanoparticles were ready by desolvation and emulsion/desolvation strategies. Encapsulation efficiency (EE%) and loading capacity (LC%) of nanoparticles ready by desolvation method were 48.four and 45.1p.c, respectively. Carvacrol-loaded nanoparticles had 132 ± 42 nm in diameter with monomodal distribution. Carvacrol-loaded nanoparticles that is ready by emulsion/desolvation technique had EE% and LC% of 32 and thirty two.three%, respectively, and 230 ± 38 nm in size. The unharness of carvacrol from nanoparticles was monitored in phosphate-buffered saline (pH = 7.4), one hundred rpm at 37°C for 10 days. About 21.fourp.c of carvacrol was released once three h from nanoparticles that were prepared by desolvation method. In emulsion/desolvation method, 26.8% of total carvacrol was released during 3 h of incubation. Cytotoxicity effect of loaded carvacrol was assessed by 3-[4, five dimethylthiazol-a pair of-yl]-2,five-diphenyltetrazolium bromide (MTT) check on gastric cancer cells line (AGS). Cell line was exposed to the free carvacrol, unloaded and carvacrol-loaded nanoparticles for forty eight h. The 0.5 maximal inhibitory concentration (IC50) at no cost carvacrol, unloaded and carvacrol-loaded HSA nanoparticles were 30, 1070 and 120 μg/ml, respectively. In conclusion, the results of this study showed applications of HSA nanoparticles for entrapment of carvacrol and antigastric cancer activity. Moreover, loading of carvacrol together with chemotherapy agents into the HSA nanoparticles may treat cancer cells better than single drug loaded nanoparticles.